- Home
- ORIC vs DNA Comparison
ORIC vs DNA Comparison
Compare ORIC & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- DNA
- Stock Information
- Founded
- ORIC 2014
- DNA 2008
- Country
- ORIC United States
- DNA United States
- Employees
- ORIC N/A
- DNA N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORIC Health Care
- DNA Health Care
- Exchange
- ORIC Nasdaq
- DNA Nasdaq
- Market Cap
- ORIC 545.5M
- DNA 562.1M
- IPO Year
- ORIC 2020
- DNA N/A
- Fundamental
- Price
- ORIC $5.53
- DNA $5.67
- Analyst Decision
- ORIC Strong Buy
- DNA Sell
- Analyst Count
- ORIC 9
- DNA 5
- Target Price
- ORIC $18.43
- DNA $17.25
- AVG Volume (30 Days)
- ORIC 734.5K
- DNA 1.2M
- Earning Date
- ORIC 05-05-2025
- DNA 05-08-2025
- Dividend Yield
- ORIC N/A
- DNA N/A
- EPS Growth
- ORIC N/A
- DNA N/A
- EPS
- ORIC N/A
- DNA N/A
- Revenue
- ORIC N/A
- DNA $227,043,000.00
- Revenue This Year
- ORIC N/A
- DNA N/A
- Revenue Next Year
- ORIC N/A
- DNA $19.36
- P/E Ratio
- ORIC N/A
- DNA N/A
- Revenue Growth
- ORIC N/A
- DNA N/A
- 52 Week Low
- ORIC $5.26
- DNA $5.26
- 52 Week High
- ORIC $14.67
- DNA $47.60
- Technical
- Relative Strength Index (RSI)
- ORIC 30.08
- DNA 30.86
- Support Level
- ORIC $5.78
- DNA $6.89
- Resistance Level
- ORIC $8.11
- DNA $7.77
- Average True Range (ATR)
- ORIC 0.52
- DNA 0.53
- MACD
- ORIC -0.14
- DNA -0.00
- Stochastic Oscillator
- ORIC 9.57
- DNA 7.48
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.